Literature DB >> 16699680

[Retinopathy in a patient with hepatitis C treated with pegylated interferon and ribavirin: case report].

Marcos Pereira de Avila1, André Moraes Freitas, David Leonardo Cruvinel Isaac, André Luis de Moura Bastos, Rafael Valadares Pena.   

Abstract

Interferon is an immunomodulating cytokine used to treat patients with different diseases, such as hepatitis C chronic infection. Pegylated interferon is a new type of interferon, developed to increase the half-life of the drug. Many side effects have been related to its use, including ocular toxicity and retinopathy. The most reported ocular findings are cotton-wool spots and hemorrhages located at the posterior pole and surrounding optic nerve head. We describe one case of pegylated interferon-associated retinopathy with visual loss. The patient had visual acuity improvement four weeks after discontinuation of the medication and the ocular findings became much more subtle.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16699680     DOI: 10.1590/s0004-27492006000200022

Source DB:  PubMed          Journal:  Arq Bras Oftalmol        ISSN: 0004-2749            Impact factor:   0.872


  1 in total

1.  Incidence of retinopathy in chronic hepatitis C patients treated with pegylated interferon alpha 2a and ribavirin combination therapy.

Authors:  Muhammad Kashif; Muhammad Khurram Saleem; Imran Khan Farooka; Amina Husnain; Arif Mahmood Siddiqui
Journal:  Pak J Med Sci       Date:  2015 Jan-Feb       Impact factor: 1.088

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.